Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Beltavac polymerized grass pollen extract in allergic rhinoconjunctivitis
2025-520581-22-00Phase 2Withdrawn
- Sponsor
- Probelte Pharma
- Start
- Jun 2025
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of Beltavac in allergic rhinoconjunctivitis (ARC) and asthma (4 arms), sponsored by Probelte Pharma. Primary endpoint: Proportion of patients with decreased conjunctival provocation test reactivity. Planned start Jun 2025; status: withdrawn.
02
Drugs
Beltavac
03
Conditions
allergic rhinoconjunctivitis (ARC)asthma
Beyond the preview
Go deeper on 2025-520581-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-520581-22-00.